Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mortality Related to Nonalcoholic Fatty Liver Disease Is Increasing in the United States
James M. Paik, Linda Henry, Leyla de Avila, et al.
Hepatology Communications (2019) Vol. 3, Iss. 11, pp. 1459-1471
Open Access | Times Cited: 187

Showing 1-25 of 187 citing articles:

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
Zobair M. Younossi, Pegah Golabi, James M. Paik, et al.
Hepatology (2023) Vol. 77, Iss. 4, pp. 1335-1347
Open Access | Times Cited: 1433
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 669
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
James M. Paik, Pegah Golabi, Youssef Younossi, et al.
Hepatology (2020) Vol. 72, Iss. 5, pp. 1605-1616
Closed Access | Times Cited: 640
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 587
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort
Tracey G. Simon, Björn Roelstraete, Hamed Khalili, et al.
Gut (2020) Vol. 70, Iss. 7, pp. 1375-1382
Open Access | Times Cited: 475
Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, et al.
Metabolism (2020) Vol. 111, pp. 154170-154170
Open Access | Times Cited: 448
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States
Zobair M. Younossi, Maria Stepanova, Janus P. Ong, et al.
Clinical Gastroenterology and Hepatology (2020) Vol. 19, Iss. 3, pp. 580-589.e5
Open Access | Times Cited: 419
AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review
Zobair M. Younossi, Kathleen E. Corey, Joseph K. Lim
Gastroenterology (2020) Vol. 160, Iss. 3, pp. 912-918
Closed Access | Times Cited: 362
Therapeutic pipeline in nonalcoholic steatohepatitis
Raj Vuppalanchi, Mazen Noureddin, Naim Alkhouri, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 6, pp. 373-392
Closed Access | Times Cited: 234
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Seong Hee Kang, Hye Won Lee, Jeong‐Ju Yoo, et al.
Clinical and Molecular Hepatology (2021) Vol. 27, Iss. 3, pp. 363-401
Open Access | Times Cited: 225
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
Mohammed Eslam, Hashem B. El–Serag, Sven Francque, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 10, pp. 638-651
Closed Access | Times Cited: 165
NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment
Johanna K. DiStefano
Endocrinology (2020) Vol. 161, Iss. 10
Open Access | Times Cited: 163
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Linda Henry, James M. Paik, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 942-956
Closed Access | Times Cited: 145
Cancer Risk in Patients With Biopsy‐Confirmed Nonalcoholic Fatty Liver Disease: A Population‐Based Cohort Study
Tracey G. Simon, Björn Roelstraete, Rajani Sharma, et al.
Hepatology (2021) Vol. 74, Iss. 5, pp. 2410-2423
Open Access | Times Cited: 137
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial
Arun J. Sanyal, Patricia López, Eric Lawitz, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 392-400
Open Access | Times Cited: 110
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 89
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Zobair M. Younossi, Saleh A. Alqahtani, Khalid Alswat, et al.
Journal of Hepatology (2023) Vol. 80, Iss. 3, pp. 419-430
Closed Access | Times Cited: 68
Metabolic dysfunction-associated steatotic liver disease and its link to cancer
Markos Kalligeros, Linda Henry, Zobair M. Younossi
Metabolism (2024) Vol. 160, pp. 156004-156004
Closed Access | Times Cited: 22
NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment
Giovanni Targher, Kathleen E. Corey, Christopher D. Byrne
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101215-101215
Open Access | Times Cited: 132
Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
Livnat Alon, Bernadette Corica, Valeria Raparelli, et al.
European Journal of Preventive Cardiology (2021) Vol. 29, Iss. 6, pp. 938-946
Open Access | Times Cited: 87
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
Marat Fudim, Lin Zhong, Kershaw V. Patel, et al.
Journal of the American Heart Association (2021) Vol. 10, Iss. 22
Open Access | Times Cited: 70
Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016
Pegah Golabi, James M. Paik, Michael Harring, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 12, pp. 2838-2847.e7
Closed Access | Times Cited: 63
Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016
Tamoore Arshad, James M. Paik, Rakesh Biswas, et al.
Hepatology Communications (2021) Vol. 5, Iss. 10, pp. 1676-1688
Open Access | Times Cited: 62
PM2.5 air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample
Trang VoPham, Nicole J. Kim, Kristin Berry, et al.
Environmental Research (2022) Vol. 213, pp. 113611-113611
Open Access | Times Cited: 53
Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality
Cheng Han Ng, Zhen Yu Wong, Nicholas Chew, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 47
Page 1 - Next Page

Scroll to top